Summary

Darapladib, a novel inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), may slow expansion of the necrotic core of atherosclerotic plaques in patients with acute coronary syndrome or other symptomatic coronary diseases, according to mixed results from the Integrated Biomarker and Imaging Study-2 [IBIS-2; NCT00268996].